Pentadeca Arginate
Also known as: PDA, pentadecapeptide arginate, BPC-157 arginate
Status
No approved product. No FDA-approved labeling. Not an approved medicine in the United States, and no approval elsewhere is listed in this site's sources. It was not evaluated separately in the FDA's compounding review; the review considered BPC-157.
What it is
An arginate salt form of the BPC-157 sequence, marketed as a more stable version.
What published research measured
The same fifteen-amino-acid sequence as BPC-157 presented as an arginate salt rather than an acetate one, on the claim that this improves stability and shelf life. The claim is about the salt form, not about the peptide doing anything different in the body. This entry does not cite separate human trial literature for this form — every efficacy claim traces back to the BPC-157 animal work, and the same caveat applies to both: no published human data was identified.
Source
Öhlund D et al. 2017 — Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer · Provenzano PP et al. 2012 — Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma · Olive KP et al. 2009 — Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.